Skip to content

CT Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine + Dexamethasone in Pain Management After Tonsillectomy

Single-center, Double-blind, Placebo-controlled Study Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine and Dexamethasone for Pain Management After Tonsillectomy

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05504967
Acronym
ORL
Enrollment
115
Registered
2022-08-17
Start date
2020-12-22
Completion date
2023-07-01
Last updated
2025-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tonsillectomy

Keywords

Tonsillectomy, Pain management

Brief summary

This study is a randomized, controlled, double-blind clinical trial to evaluate the effect of local infiltration of ropivacaine and dexamethasone, alone or in association, in the reduction of pain and the need for supplementary analgesia, after tonsillectomy, in the immediate and late postoperative period, in individuals aged 18 to 65 years. The present clinical trial will include 4 study groups, each with different content of infiltration into the amygdaline locus. One group will have ropivacaine in the infiltration, the other will have dexamethasone and another the association of these two drugs. In order to better understand the effectiveness of these drugs, there will also be a control group, in which saline solution will be infiltrated. Approximately 104 individuals, aged 18 to 65 years, proposed for tonsillectomy will be included in the study, i.e., 26 subjects in each study group. Postoperative pain will be characterized by self-assessment through the Visual Analog Scale (VAS, 100mm) at various moments of the study, namely in the preoperative consultation, in the pre-anesthetic consultation, at hospital admission and in the postoperative period until the 15th day after the surgery. The aim of this study is not to eliminate intra and postoperative analgesia, but rather account for the need for analgesia depending on the different infiltration content peramygdalin. For this, in the postoperative period, a careful pain monitoring, having first-line analgesic and rescue medication for use immediate response in the face of minimal pain assessed by validated pain scales. It is intended, therefore, to record which analgesic drugs and in what doses were necessary.

Interventions

DRUGOradexon

With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

DRUGRopivacaine

With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

DRUGSaline solution

With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

Sponsors

Clinical Academic Center (2CA-Braga)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

randomized, controlled, double-blind clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists (ASA) physical status I-II; * Surgical proposal of tonsillectomy; * Tonsillectomy performed by the cold shedding technique; * History of recurrent tonsillitis, caseous tonsillitis and / or peritonsillar abscess;

Exclusion criteria

* Use of chronic analgesic medication; * ASA III-IV; * Coagulation disorders, such as von Willebrand disease or diagnosis of other platelet disorders, haemophilia A and B, or diseases that may develop with hemostatic dysfunction; * Intolerance or allergy to any of the drugs used in the study; * Suspicious or confirmed diagnosis of neoplastic disease; * Fever or acute respiratory tract infection in the last 3 weeks;

Design outcomes

Primary

MeasureTime frameDescription
Time to onset of water intake, liquid and solid oral dietTime since the end of surgery until post-operative visit (15 days after surgery)Time to onset of water intake, liquid and solid oral diet, since the end of surgery (minutes)
Change in pain assessment using the VASChange from baseline (90 days before surgery; day of surgery, day 1, 2, 3, 7 and 15 after surgery)Alteration in Visual Analogue Scale values (1-100mm) to assess pain at rest and during swallowing
Time to first administration of analgesiaFrom the day of surgery to discharge (an average 1 day)Time until it is needed to administer analgesia to the patient, after surgery (in minutes)
Paracetamol intakeTime since the end of surgery until post-operative visit (15 days after surgery)Number of paracetamol intakes
Paracetamol cumulative dosage intakeTime since the end of surgery until post-operative visit (15 days after surgery)Cumulative dosage of paracetamol intake in mg
Rescue analgesia intakeTime since the end of surgery until post-operative visit (15 days after surgery)Number of rescue analgesia intakes (tramadol)
Need of PethidineImmediate post-surgeryNeed of pethidine in immediate post-surgery (yes/no)
Time to need of PethidineTime since the end of surgery until post-operative visit (15 days after surgery)Time until pethidine admnistration is needed, since the end of surgery (minutes)

Secondary

MeasureTime frameDescription
Safety outcomeTime since screening until post-operative visit (15 days after surgery)Number of adverse events

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026